Atlas Trials

Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

Clinical trial NCT05910710 · UNKNOWN

Trial details

NCT number
NCT05910710
Sponsor
Samsung Medical Center
Status
UNKNOWN
Study type
OBSERVATIONAL
Triple Negative Breast CancerNeoadjuvant ChemotherapyPembrolizumabTumor Microenvironment
Start date
2023-03-02
Primary completion
2025-12-31
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.